雄激素受体在三阴性乳腺癌治疗与预后中作用的研究进展

Advances in androgen receptor in treatment and prognosis of triple negative breast cancer

三阴性乳腺癌(triple negative breast cancer,TNBC)的恶性程度高,尤其在青年女性中发病率更高,易发生早期转移和化疗耐受,目前仍缺乏有效的临床治疗靶点,预后极差。研究发现,雄激素受体(androgen receptor,AR)在TNBC组织中高表达,与TNBC的预后紧密相关,并且AR能够促进TNBC细胞的生长和转移。当前,临床上单一采用抗雄激素药物治疗TNBC已显示出一定的敏感性,而AR抑制剂联合其他经典靶向治疗药物对于TNBC的治疗更具有潜在的价值。AR作为TNBC预后的一个重要参考指标,抗AR治疗在TNBC中的研究已引起一定的关注。本文就抗AR治疗在TNBC中可能的机制和临床研究进行综述。

Triple negative breast cancer (TNBC) has a high degree of malignacy, and a higher incidence among young women. It is prone to early metastasis and chemotherapy tolerance, lacks effective clinical treatment targets, and has a poor prognosis. Many studies have found that androgen receptor (AR) can be highly expressed in TNBC tissues, which is closely related to the prognosis of TNBC. AR has been proved to promote the growth and metastasis of TNBC cells. The clinical data show that the single anti-androgen drug therapy shows the sensitivity to TNBC, and the combination of AR inhibitor and other classic targeted therapy drugs has potential value for the treatment of TNBC. Because AR is a reference indicator for the prognosis of TNBC, the studies on anti-AR therapy in TNBC have attracted considerable attention. This review discusses the therapeutic mechanism and clinical research of anti-AR therapy in TNBC.